Folr1–3 are known to bind folate by a newly described mechanism, and the heightened expression of Folr1 and Folr2 in disease-causing cells in cancers and inflammatory diseases has led to extensive research into folate receptor-targeted therapies [19–22]. This evidence concerns the gene FOLR1 and cancer.